Substituted porphyrins

• US 6,544,975 B1
• Filed: 01/25/2000
• Issued: 04/08/2003
• Est. Priority Date: 01/25/1999
• Status: Expired due to Term

• Current Assignee: Aeolus Sciences Incorporated, Duke University, Goodnow Capital, L.L.C., National Jewish Medical and Research Center
• Original Assignee: Aeolus Pharmaceuticals, Inc., Duke University, National Jewish Medical and Research Center
• Inventors: Kitchen, Douglas B., Day, Brian J., Fridovich, Irwin, Trova, Michael P., Batinic-Haberle, Ines, Crapo, James D., Gauuan, Polivina Jolicia F.
• Primary Examiner(s): Raymond, Richard L.
• Application Number:
  US09/490,537
• Time in Patent Office: 1,169 Days
• Field of Search: 540/145, 514/185, 514/365, 514/383, 514/397, 514/406, 514/410
• US Class Current: 514/185
• CPC Class Codes: A61K 31/409 having four such rings, e.g. porphine derivatives, bilirubin, biliverdine hemin, hematin A61K31/555
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 487/22 in which the condensed system contains four or more hetero rings
• CPC Class Codes: C09B 47/00 Porphines; Azaporphines non-dyeing compounds C07D487/22

Abstract

The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

Claims

1. A compound of Formula I or II

or, when said compound bears a charge, a pharmaceutically acceptable salt thereof, wherein

R₁ and R₃ are the same and are:

R₂ and R₄ are the same and are;

Y is halogen or —

CO₂X, and

each X is the same or different and is an alkyl and each R₅ is the same or different and is H or alkyl, and

M is a metal selected from the group consisting of zinc, iron, nickel, cobalt, copper and manganese.

wherein when R₁ and R₃ are —

H, R₂ and R₄ are not

or

when R₁ and R₃ are —

H, and R₂ and R₄ are

said compound is of Formula II and M is a metal selected from the group consisting of manganese, iron, copper, cobalt and nickel.

2. The compound according to claim 1 wherein R₁ and R₃ are the same and are:

R₂ and R₄ are the same and are;

Y is —

F or —

CO₂X, and

X is the same or different and is a C_1-4 alkyl and each R₅ is the same or different and is H or C_1-4 alkyl.

3. The compound according to claim 2 wherein X is methyl or ethyl.

4. The compound according to claim 1 wherein R₁, R₂, R₃ and R₄ are the same.

5. The compound according to claim 1 wherein R₁, R₂, R₃ and R₄ are

6. The compound according to claim 5 wherein X is methyl or ethyl.

7. The compound according to claim 5 wherein R₁, R₂, R₃ and R₄ are the same.

8. The compound according to claim 7 wherein R₁, R₂, R₃ and R₄ are

9. The compound according to claim 1 wherein said compound is of Formula II.

10. The compound according to claim 9 wherein M is manganese.

11. A composition comprising the compound of claim 1 and a carrier.